InvestorsHub Logo
Followers 4
Posts 1195
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Saturday, 04/16/2016 4:36:00 PM

Saturday, April 16, 2016 4:36:00 PM

Post# of 369
PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients


There were 10 RECIST complete or partial responses (CR/PR) out of 37 (15 BRCA m) evaluable pts, including gBRCA m breast (n=4), platinum-resistant gBRCA m ovarian (n=2), BRCA wildtype (WT) triple negative breast (n=1), BRCA WT ovarian (n=2) and BRCA unknown prostate (n=1) cancer pts.


http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=946fbd6f-3560-4ea2-aed6-7788155ea81b&cKey=fbf921a7-552a-44ee-aa04-a345ece10ad8&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267